IFNA1 and renal cell adenocarcinoma: For example, while one re-analysis showed that IFN-α therapy was beneficial on the OS of RCC patients compared to conventional therapy, supported by suggestive evidence, another re-analysis showed targeted therapy was more beneficial on the OS of RCC patients compared to IFN-α therapy, supported by weak evidence (Table 2).